What did a basket trial evaluating tazemetostat allow investigators to assess?

The basket trial evaluating tazemetostat permitted investigators to study its efficacy in various types of cancers that share a common genetic mutation, specifically mutations in the EZH2 gene. This approach is beneficial because it allows for an assessment of the drug's effectiveness across multiple indications, facilitating the understanding of targeted therapies that can benefit patients with different tumors exhibiting the same underlying genetic alteration. By grouping cancers with a similar mutation, researchers can streamline their investigations and potentially expedite the development of personalized treatment options.

This type of trial design is particularly advantageous as it promotes a more tailored approach to cancer treatment, focusing on the biology of the tumors rather than their locations or histological types. The other options do not accurately reflect the primary aim of the basket trial concerning tazemetostat and its ability to provide insights into the drug's efficacy based on genetic characteristics shared among different cancers.